NASDAQ:CNMD - CONMED Stock Price, News, & Analysis

CONMED trades on the NASDAQ under the ticker symbol "CNMD."

CONMED declared a quarterly dividend on Friday, November 9th. Shareholders of record on Friday, December 14th will be paid a dividend of $0.20 per share on Monday, January 7th. This represents a $0.80 dividend on an annualized basis and a yield of 1.18%. The ex-dividend date is Thursday, December 13th. View CONMED's Dividend History.

CONMED Co. (NASDAQ:CNMD) announced its quarterly earnings data on Thursday, November, 1st. The medical technology company reported $0.46 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.45 by $0.01. The medical technology company had revenue of $202.30 million for the quarter, compared to analyst estimates of $198.51 million. CONMED had a return on equity of 9.51% and a net margin of 8.56%. The firm's quarterly revenue was up 6.4% on a year-over-year basis. During the same period last year, the firm earned $0.42 earnings per share. View CONMED's Earnings History.

CONMED is scheduled to release their next quarterly earnings announcement on Wednesday, January 30th 2019. View Earnings Estimates for CONMED.

CONMED updated its FY18 earnings guidance on Thursday, November, 1st. The company provided earnings per share guidance of $2.15-2.20 for the period, compared to the Thomson Reuters consensus estimate of $2.17. CONMED also updated its FY 2018 guidance to $2.15-2.20 EPS.

3 equities research analysts have issued twelve-month target prices for CONMED's shares. Their forecasts range from $78.00 to $83.00. On average, they anticipate CONMED's stock price to reach $80.6667 in the next twelve months. This suggests a possible upside of 19.3% from the stock's current price. View Analyst Price Targets for CONMED.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CONMED in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for CONMED.

Press coverage about CNMD stock has trended very positive on Monday, InfoTrie reports. The research firm ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. CONMED earned a coverage optimism score of 3.1 on InfoTrie's scale. They also gave news headlines about the medical technology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the next few days.

Some companies that are related to CONMED include LivaNova (LIVN), Masimo (MASI), GETINGE AB/ADR (GNGBY), NxStage Medical (NXTM), AxoGen (AXGN), Natus Medical (BABY), Viewray (VRAY), Cutera (CUTR), Rockwell Medical (RMTI), BioLife Solutions (BLFS), Electrocore (ECOR), Semler Scientific (SMLR), Fonar (FONR), Zynex (ZYXI) and Stereotaxis (STXS).

CONMED's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (14.34%), Dimensional Fund Advisors LP (6.24%), Capital Research Global Investors (6.11%), Scopia Capital Management LP (4.28%), Macquarie Group Ltd. (2.81%) and Victory Capital Management Inc. (2.71%). Company insiders that own CONMED stock include Charles Farkas, Curt R Hartman, Daniel Jonas, Dirk Kuyper, Heather L Cohen, Jo Ann Golden, Luke A Pomilio, Mark E Tryniski, Nathan Folkert, Peter K Shagory, Stanley W Peters III and Terence M Berge. View Institutional Ownership Trends for CONMED.

CNMD stock was sold by a variety of institutional investors in the last quarter, including Scopia Capital Management LP, Victory Capital Management Inc., Dimensional Fund Advisors LP, William Blair Investment Management LLC, Alliancebernstein L.P., Fisher Asset Management LLC, JPMorgan Chase & Co. and JPMorgan Chase & Co.. Company insiders that have sold CONMED company stock in the last year include Daniel Jonas, Jo Ann Golden, Luke A Pomilio, Nathan Folkert, Peter K Shagory, Stanley W Peters III and Terence M Berge. View Insider Buying and Selling for CONMED.

CNMD stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Capital Research Global Investors, O Shaughnessy Asset Management LLC, Putnam Investments LLC, American Century Companies Inc., Los Angeles Capital Management & Equity Research Inc., Panagora Asset Management Inc. and Man Group plc. Company insiders that have bought CONMED stock in the last two years include Charles Farkas, Curt R Hartman, Heather L Cohen and Mark E Tryniski. View Insider Buying and Selling for CONMED.

Shares of CNMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CNMD stock can currently be purchased for approximately $67.61.

CONMED has a market capitalization of $1.93 billion and generates $796.39 million in revenue each year. The medical technology company earns $55.48 million in net income (profit) each year or $1.89 on an earnings per share basis. CONMED employs 3,100 workers across the globe.

The official website for CONMED is http://www.conmed.com.

CONMED's mailing address is 525 FRENCH ROAD, UTICA NY, 13502. The medical technology company can be reached via phone at 315-797-8375.